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It has been shown that a prolonged low-dose corticosteroid treatment attenuates
the severity of inflammation and the intensity and duration of organ system
failure. In the present study, we determined whether low-dose methylprednisolone
(a synthetic glucocorticoid) can protect male Wistar rats against cardiac pumping
defects caused by lipopolysaccharide-induced chronic inflammation. For the
induction of chronic inflammation, a slow-release ALZET osmotic pump was
subcutaneously implanted to infuse lipopolysaccharide (1mg kg−1 d−1) for 2 weeks.
The lipopolysaccharide-challenged rats were treated on a daily basis with intraperitoneal
injection of methylprednisolone (5mg kg−1 d−1) for 2 weeks. Under conditions of
anesthesia and open chest, we recorded left ventricular (LV) pressure and ascending
aortic flow signals to calculate the maximal systolic elastance (Emax) and the theoretical
maximum flow (Qmax), using the elastance-resistance model. Physically, Emax reflects
the contractility of the myocardium as an intact heart, whereas Qmax has an inverse
relationship with the LV internal resistance. Compared with the sham rats, the
cardiodynamic condition was characterized by a decline in Emax associated with
the increased Qmax in the lipopolysaccharide-treated rats. Methylprednisolone therapy
increased Emax, which suggests that the drug may have protected the contractile
status from deteriorating in the inflamed heart. By contrast, methylprednisolone therapy
considerably reduced Qmax, indicating that the drug may have normalized the LV
internal resistance. In parallel, the benefits of methylprednisolone on the LV systolic
pumping mechanics were associated with the reduced cardiac levels of negative
inotropic molecules such as peroxynitrite, malondialdehyde, and high-mobility group
box 1 protein. Based on these data, we suggested that low-dose methylprednisolone
might prevent lipopolysaccharide-induced decline in cardiac intrinsic contractility and LV
internal resistance, possibly through its ability to reduce the aforementioned myocardial
depressant substances. However, since our results were obtained in anesthetized
open-chest rats, extrapolation to what may occur in conscious intact animals should be
done with caution.
Keywords: high-mobility group box 1, inflammation, malondialdehyde, maximal systolic elastance, peroxynitrite,
theoretical maximum flow
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INTRODUCTION
Inflammatory disorders such as allergies, asthma, autoimmune
diseases, and sepsis are a major cause of illness and death (Cooper
and Stroehla, 2003; Riedemann et al., 2003). Lipopolysaccharide
(LPS), which is the major bioactive component of the cell
membrane of gram-negative bacteria, may promote and amplify
inflammatory responses, generating various cardiodepressive
mediators (Garner et al., 2003; Carlson et al., 2005; Andreasen
et al., 2008). In LPS-induced inflammation, an excessive and
prolonged production of nitric oxide (NO) exerts adverse effects
on the heart (Kleinert et al., 2004). NO at supraphysiological
levels may react with superoxide anions to generate highly toxic
compounds such as peroxynitrite to damage cardiac myocytes
(Ishida et al., 1996; Khadour et al., 2002). LPS also induces the
secretion of high-mobility group box 1 (HMGB1) protein in the
myocardium, which may be detrimental to the contractile status
of the left ventricle (Li et al., 2006; Xu et al., 2010).
Corticosteroids have been used in the treatment of severe
sepsis and septic shock for more than 50 years (Annane
et al., 2009). The therapeutic effects of corticosteroids have
been characterized by their ability to exert antiinflammatory
and immunosuppressive efficacy. Methylprednisolone (MP) is
a synthetic glucocorticoid, which can suppress inducible NO
synthase (iNOS) expression and other inflammatory molecules
through its ability to inhibit nuclear factor-κB (NF-κB) activation
(Xu et al., 1998). In 2003, Annane and Cavaillon have shown that
a low-dose hydrocortisone can reverse the systemic inflammatory
response in subjects secondary to an infection. Moreover,
a prolonged low-dose corticosteroid treatment attenuates the
severity of inflammation and the intensity and duration of
organ system failure (Keh et al., 2003; Oppert et al., 2005).
We previously demonstrated that low-dose MP therapy prevents
peripheral vasodilation, but stiffens aortas and elastic arteries in
rats with LPS-induced chronic inflammation (Ko et al., 2013).
Although, MP therapy increases aortic stiffness, the question that
remains unanswered is whether LPS-induced impaired cardiac
function can be improved by MP therapy associated with the
attenuation of cardiosuppressing mediators.
The physical properties of the left ventricle could be reflected
in the behavior of the ventricular pressure, volume, and flow
(Hunter et al., 1983; Shroff et al., 1983). The relationship
between instantaneous ventricular pressure and volume has
been considered a time-varying elastance (Sagawa, 1978). The
viscouslike behavior can be described as the ventricular pressure-
flow relation and can be represented as ventricular internal
resistance (Hunter et al., 1983; Shroff et al., 1983; Campbell et al.,
1986). For an ejecting beat, the left ventricle as a mechanical
pump can be characterized by both themaximal systolic elastance
(Emax) and the theoretical maximum flow (Qmax) (Campbell
et al., 1986; Shroff et al., 1992). Hunter et al. (1983) showed
Abbreviations: CO, cardiac output; CRP, C-reactive protein; Emax, maximal
systolic elastance; HMGB1, high-mobility group box 1; HR, basal heart
rate; IL-6, interleukin-6; LPS, lipopolysaccharide; LV, left ventricular; MDA,
malondialdehyde; MP, methylprednisolone; NO, nitric oxide; Qmax, theoretical
maximum flow; Pes, LV end-systolic pressure; Piso, LV isovolumic pressure; Pisomax,
peak LV isovolumic pressure; Veed , effective LV end-diastolic volume.
that Emax can serve as a reliable index of ventricular contractility
because it is independent of preload and afterload, but it is
sensitive to changes in the contractile status of the myocardium.
Shroff et al. (1992) reported thatQmax has an inverse relationship
with the LV internal resistance, which can be associated with the
structural, biochemical, or geometric alterations.
In the present study, we investigated whether low-dose
MP therapy can protect male Wistar rats against cardiac
pumping defects caused by lipopolysaccharide-induced chronic
inflammation. For the induction of chronic inflammation, a slow-
release ALZET osmotic pump was subcutaneously implanted to
infuse LPS (1mg kg−1 d−1) for 2 weeks. The LPS-challenged
rats were treated on a daily basis with intraperitoneal injection
of MP (5mg kg−1 d−1) for 2 weeks. We recorded the LV
pressure and ascending aortic flow signals to calculate the Emax
and the Qmax, using the elastance–resistance model (Campbell
et al., 1986; Shroff et al., 1992). We also measured myocardial
depressant substances such as peroxynitrite and HMGB1 in
the LPS-treated rats after MP therapy. Furthermore, the level
of cardiac malondialdehyde (MDA) was measured and served
as an indirect index of reactive oxygen species (ROS) activity
(Gutteridge and Halliwell, 1990).
METHODS
Animals
We used male Wistar rats, weighing 250–300 g, as experimental
animals, which were randomly divided into 4 groups (n =
10/group): (i) Sham group, (ii) Sham group treated with MP
(Sham-MP), (iii) LPS group, and (iv) LPS group treated with MP
(LPS-MP). The range of the applied LPS dosage in rodent was
reported from 5µg kg−1 to 5mg kg−1 (Noworyta-Sokołowska
et al., 2013). In this study, for low-grade chronic inflammation
(Smith et al., 2009), a slow-release ALZET osmotic pump
(Model 2004; DURECT Corporation, Cupertino, CA, USA)
was subcutaneously implanted to infuse LPS (Escherichia coli
O55:B5, 1mg kg−1 d−1; Sigma–Aldrich, St. Louis, MO, USA)
for 2 weeks. The sham group was infused with saline. Both
the Sham-MP and the LPS-MP groups were treated on a daily
basis with intraperitoneal injection of low-dose MP (5mg kg−1
d−1; Pfizer Manufacturing Belgium NV, Puurs, Belgium) for 2
weeks (Ko et al., 2013). The animals were allowed free access
to Purina chow and water with a 12-h light–dark cycle. All
experiments were conducted according to the Guide for the
Care and Use of Laboratory Animals. The Animal Care and Use
Committee of National Taiwan University approved the study
protocol.
Measurement of Plasma Levels of Free
Fatty Acids (FFA)
Using cardiac puncture technique, blood samples were collected
at the end of catheterization. The collected blood samples were
subsequently centrifuged at 1600 g at 4◦C for 10min to determine
the plasma levels of FFA by using enzymatic kits (Cayman,
Ann Arbor, MI, USA and Biovision, Mountain View, CA, USA)
(Okabe et al., 1980).
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Proinflammatory Cytokine Measures
We have previously described procedures to measure
proinflammatory cytokines (Ko et al., 2013). In brief, plasma
interleukin (IL)-6 (R&D Systems, Minneapolis, MN, USA),
C-reactive protein (CRP) (ALPCO, Windham, NH, USA),
nitrogen oxides (NO, nitrites + nitrates) (Calbiochem, Merck,
Germany), and cardiac peroxynitrite (Cayman Chemical, Ann
Arbor, MI, USA) levels were quantified using commercially
available enzyme-linked immunosorbent assay kits in strict
accordance with the manufacturer’s instructions.
Immunohistochemical Staining for
Inflammatory Cells and Markers in the
Myocardium
To examine inflammatory cells and markers in the myocardium,
we measured CD68 as macrophage marker and receptor for
advanced glycation end products (RAGE) as inflammatory
marker.
We have previously described general procedures for
immunohistochemical staining technique (Ko et al., 2013).
In brief, formalin-fixed rat cardiac tissues were embedded
in paraffin, cut into 4-µm-thick sections, and stained with
hematoxylin and eosin (H&E). Immunohistocytochemical
staining was performed using mouse monoclonal anti-CD68 IgG
(MCA341GA) (1:25; AbD Serotec., UK) and goat anti-human
RAGE IgG (1:200; AbD Serotec., UK) antibodies in a BenchMark
ULTRA slide stainer, and samples were analyzed using an iView
Universal DAB Detection kit (Ventana Medical Systems).
Western Blotting for Cardiac HMGB1
Protein
We have previously described procedures for Western
blotting technique (Ko et al., 2013). In brief, Rat cardiac
tissue protein samples (50µg/lane) were resolved using 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
electrotransferred onto polyvinylidene difluoride (PVDF)
membranes, which were incubated with a primary monoclonal
anti-HMGB1antibody (1:10000; Epitomics, Burlingame, CA,
USA) at 4◦C overnight, and then incubated with a horseradish
peroxidase (HRP)-conjugated secondary immunoglobulin G
(IgG) antibody. Immunoreactive bands were visualized using
enhanced chemiluminescence (ECL) reagents from PerkinElmer.
Relative quantity was obtained by normalizing the density of
the target protein against that of β-actin. Experiments were
replicated 3 times, and the results are expressed as the mean ±
standard error (s.e.).
Estimation of Cardiac MDA Level by
Thiobarbituric Acid Assay
In this study, thiobarbituric acid reactive substance (TBARS) was
used as an estimate of cardiac MDA level, because MDA is not
the only physiological molecule that can react with thiobarbituric
acid (Del Rio et al., 2005).
We have previously described procedures for measuring
MDA/TBARS (Wang et al., 2013). In brief, rat cardiac tissues
were stored at −80◦C until further analysis. All tissues were
homogenized in the RIPA buffer (Sigma Chemical Co., St.
Louis, MO, USA) with a 1% protease inhibitor cocktail (Sigma
Chemical Co.) and centrifuged at 1600 g at 4◦C for 10min to
obtain supernatants for measuring cardiac MDA level. LV MDA
levels were estimated by TBARS by using a commercial kit
(Cayman Chemical Company, Ann Arbor, MI, USA) (Beuge and
Aust, 1978). Protein concentrations of the left ventricle were
assayed using the Bradford method (DCProtein Assay; Bio-Rad)
(Bradford, 1976).
Catheterization
General surgical procedures and measurement of cardiodynamic
variables have previously been described in anesthetized rats
(Chang et al., 2002). In brief, the rats were anesthetized with
sodium pentobarbital (50mg kg−1, i.p.), placed on a heating
pad, and intubated and ventilated with a Model 131 rodent
respirator (New England Medical Instruments, Medway, MA,
USA). The rectal temperature of each rat was measured by
using clinical thermometer. The chest was opened through
the second intercostal space of the right side. The pulsatile
aortic flow was recorded by using an electromagnetic flow
probe, Model 100 series, with an internal circumference of
8mm (Carolina Medical Electronics, King, NC, USA), which
was positioned around the ascending aorta. The LV pressure
was measured by using a high-fidelity pressure catheter,
Model SPC 320 of size 2F (Millar Instruments, Houston,
TX, USA), which was inserted through the isolated right
carotid artery into the left ventricle. An ECG/Biotach amplifier
(Gould, Cleveland, OH, USA) was used to record lead II
electrocardiogram (ECG). Using the peak R wave of ECG
as a fiducial point, we selected the LV pressure and aortic
flow signals of 5–10 beats and averaged these signals in
the time domain. To characterize the pumping mechanics
of an inflamed heart, a single-beat estimation technique was
performed to generate model parameters for calculating the
systolic elastance and resistance (Chang and Kuo, 1997; Chang,
1998).
Prediction of the LV Pressure by Using the
Elastance–resistance Model
We have previously described procedures for characterizing the
cardiac pumping mechanics from the elastance-resistance model
(Wu et al., 2008; Wang et al., 2013). In brief, one can predicted
the model-derived pressure of the left ventricle
∧
P(t) if the
model parameters could be previously identified (Campbell et al.,
1986; Shroff et al., 1992). The following equation describes the
relationship between the instantaneous LV pressure, isovolumic
pressure, and aortic flow:
∧
P(t) = Piso(t)
[
1−
Vej(t)
Veed
] [
1−
Q(t)
Qmax
]
(1)
Vej(t) is the instantaneous ejected volume, which was computed
by numerically calculating the running integral of the aortic flow
signal Q(t). Qmax is the theoretical maximum flow, Veed is the
effective LV end-diastolic volume that is the volume difference
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between the LV end-diastolic volume and the zero-pressure
volume axis intercept, and Piso(t) is the isovolumic pressure
obtained by occluding the ascending aorta near the sinuses of
Valsalva at the end of diastole. In this study, Piso(t) was derived
from the measured pressure of an ejection contraction by using
a nonlinear least-squares approximation technique, as follows
(Sunagawa et al., 1980):
Piso(t) =
1
2
Pidmax
[
1− cos(ωt + c)]+ Pd
]
(2)
Pidmax is the peak-developed isovolumic pressure, ω is the
angular frequency, c is the phase-shift angle of the sinusoidal
curve, and Pd is the LV end-diastolic pressure. The isovolumic
pressure Piso(t) (green curve in Figure 1B) was obtained by
fitting the measured LV pressure curve segments from the
end-diastolic pressure point to the peak +dP/dt and from
the pressure point of the peak –dP/dt to the same level as
the end-diastolic pressure of the preceding beat (Takeuchi
et al., 1991). The LV end-diastolic point was identified
using the peak of the ECG R wave. The estimated peak
isovolumic pressure Pisomaxis the pressure sum of Pidmax
and Pd.
Both Veed and Qmax in Equation (1) are the model parameters
remained to be determined. Campbell et al. (1986) demonstrated
that Equation (1) can be used to fit the measured LV pressure of
an ejecting beat precisely, if the fitting interval is tej< t < tpisomax,
where tej is the onset of ventricular ejection and tpisomaxis the
time of peak isovolumic pressure. The Nelder–Meade simplex
algorithm was used in a nonlinear least-squares manner to
iteratively adjust Veed and Qmax to minimize the root-mean-
square error (ep) (Dennis and Woods, 1987). The parameters
coincident with the minimum ep were recorded as the model
estimates of the LV systolic pumping mechanics (green curves
in Figures 1C,D). Thus, the LV systolic elastance was calculated
using E(t) = Piso(t)/Veed, and its maximal value is the maximal
systolic elastance (Emax = Pisomax/Veed). The internal resistance
of the left ventricle was expressed as R(Piso) = Piso(t)/Qmax (Shroff
et al., 1992).
LV End-systolic Equilibrium Point
We have previously described procedures for defining the LV
end-systolic equilibrium point (Wang et al., 2013). In brief, the
FIGURE 1 | Procedures for the estimation of cardiodynamic parameters using the elastance-resistance model in a sham rat. In Graph (A), the red curve
shows the measured Q(t). In Graph (B), the isovolumic portions of the measured P(t) (the red curve) were used to estimate the Piso(t) (the green line) using (Equation 1).
Taking Q(t) and Piso (t) as 2 inputs into (Equation 2), a good similarity between the computed and measured P(t) was observed when the (Equation 2) was fit over tej< t <
tpisomax, as shown in (C,D). In Graph (C), themeasured data are described in terms of the red line; themodel-derived data are represented by the green line. In Graph (D),
the scatter diagram between measured and model-generated data is described by using the green line. The red line is the simple linear regression line of measured and
model-generated data, with a slope of approximately 1 (0.973). Thus, themodel parameters Veed andQmax were determinedwith theminimum ep. ep, root-mean-square
error; LV, left ventricular; P(t), measured LV pressure; Piso (t), estimated LV isovolumic pressure; P(t)/Piso(t), ratio of P(t) to Piso (t); Q(t), measured ascending aortic flow;
Qmax, theoretical maximum flow; tej , the onset of ventricular ejection; tpisomax, the time of the peak isovolumic pressure; Veed , effective LV end-diastolic volume.
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time integration of aortic flow (red curve in Figure 2A) and
the measured LV pressure (red curve in Figure 2B) were used
to construct the pressure-ejected volume loop. After drawing a
tangential line from the estimated Pisomax to the right corner
of the pressure-ejected volume loop, we then obtained a point
referred to as the end-systolic equilibrium point (Barnea and
Jaron, 1990; Chang, 1998), as shown in Figure 2C. The pressure
at this equilibrium point is the LV end-systolic pressure (Pes).
Statistical Analysis
Results are expressed as the mean ± s.e. Two-way ANOVA
was used to determine the statistical significance, when multiple
comparisons were made among the effects of LPS and MP on
cardiodynamic and biochemical data. Significant differences were
assumed at the level of P < 0.05. If the ANOVA results for
any cardiodynamic or biochemical variable reached the level of
significance, then Tukey’s honestly significant difference method
was used to determine which groups of rats had different mean
values of that variable.
RESULTS
Compared with the age-matched shams, there were no significant
differences in the body weight (BW), whole heart weight,
LV weight (LVW), and LVW/BW ratio in the LPS-challenged
animals, as shown in Table 1. Although, MP therapy markedly
reduced heart weight, BW and LVW, it did not alter the LVW/BW
ratio in the LPS-treated rats. By contrast, only BW was decreased
by MP in the Sham group. Neither LPS nor MP affected HR. By
contrast, an increase in CO associated with the decreased Pes was
observed in the LPS-treated rats. However, these 2 parameters
did not respond to MP therapy. MP therapy for 2 weeks had
improved dP/dtmax and dP/dtmin, which were impaired by LPS
challenge. Those hemodynamic variables were not affected byMP
in the Sham-MP group.
As for the inflammatory cytokines, MP therapy attenuated the
LPS-induced increase in the plasma CRP, IL-6, and NO levels,
as shown in Table 2. By contrast, the plasma FFA levels were
elevated by treating both the sham and LPS rats with MP.
FIGURE 2 | Identification of the LV end-systolic equilibrium point in the same rat as shown in Figure 1. The time integration of Q(t) (A) and the measured P(t)
(red curve in B) were used to construct the pressure-ejected volume loop (green curve in C). In Graph (B), the isovolumic portions of the measured P(t) were used to
estimate the Piso(t) (the green line) using (Equation 1). In (C), drawing a tangential line from Pisomax to the right corner of the pressure-ejected volume loop yields a
point referred to as the end-systolic equilibrium point. LV, left ventricular; P(t), measured LV pressure; Piso(t), estimated LV isovolumic pressure; Pisomax, estimated
peak LV isovolumic pressure; Q(t), measured ascending aortic flow.
TABLE 1 | Basic and hemodynamic data in the LPS-challenged rats treated with MP.
Sham (n = 10) Sham-MP (n = 10) LPS (n = 10) LPS-MP (n = 10)
BW 355.0±9.8 332.3± 13.8† 376.2± 9.3 318.8±7.2‡
Heart weight 1.01±0.03 0.94± 0.05 1.07± 0.04 0.89±0.04‡
LVW 0.66±0.02 0.65± 0.03 0.69± 0.03 0.61±0.02‡
LVW/BW 1.85±0.05 1.89± 0.08 1.89± 0.07 1.91±0.06
RT 36.2±0.2 36.4± 0.1 36.6± 0.2 36.5±0.2
HR 424.8±10.5 423.7± 11.8 424.1± 13.0 443.4±10.2
CO 1.943±0.132 2.170± 0.133 2.541± 0.094† 2.456±0.095
Pes 125.5±4.9 108.7± 2.8 102.2± 4.2
† 111.9±4.5
dP/dtmax 10503.9±503.6 10460.7± 417.2 8720.9± 438.9
† 10847.1±630.5‡
dP/dtmin −7605.7±265.1 −7011.7± 225.5 −6121.4± 311.3
† −7726.2±302.7‡
All values are expressed as the mean ± s.e. BW, body weight (g); CO, cardiac output (mL s−1); dP/dtmax (mmHg s
−1); dP/dtmin (mmHg s
−1); HR, basal heart rate (beats min−1 );
LVW, left ventricular weight (g); LVW/BW, LVW to BW ratio (mg/g); Pes, LV end-systolic pressure (mmHg); RT, rectal temperature (
◦C); LPS, lipopolysaccharide; MP, methylprednisolone;
LPS-MP, LPS rats treated with MP; Sham-MP, Sham treated with MP.
†P < 0.05 from the sham group.
‡P < 0.05 from the LPS group.
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TABLE 2 | Proinflammatory cytokines and plasma FFA in the
LPS-challenged rats treated with MP.
Sham Sham-MP LPS LPS-MP
(n = 10) (n = 10) (n = 10) (n = 10)
CRP 256.4 ± 13.0 268.0± 14.4 359.0 ± 19.3† 307.3 ± 16.1‡
IL-6 25.8 ± 1.8 27.3 ± 2.1 53.7 ± 5.9† 32.3 ± 4.5‡
NO 16.1 ± 1.8 17.9 ± 1.1 35.3 ± 1.8† 21.4 ± 1.6‡
FFA 0.88 ± 0.01 0.93 ± 0.02† 0.86 ± 0.05 0.93 ± 0.10‡
All values are expressed as the mean ± s.e. CRP, plasma C-reactive protein (mg mL−1 );
FFA, free fatty acid (mM); IL-6, plasma interleukin-6 (pg mL−1 ); NO, plasma nitrites
and nitrates (µM); LPS, lipopolysaccharide; MP, methylprednisolone; LPS-MP, LPS rats
treated with MP; Sham-MP, Sham treated with MP.
†P < 0.05 from the sham group.
‡P < 0.05 from the LPS group.
The red curves in Figures 1A,B show the measured ascending
aortic flow signal and LV pressure waveform, respectively, in a
sham rat. The green line in Figure 1B represents the isovolumic
pressure–time curve at the measured end-diastolic volume,
which was estimated by fitting a sinusoidal function to the
isovolumic portions of the measured LV pressure. Similarity
between the computed and measured LV pressure waveforms
during the fitting interval tej< t < tpisomax was shown in
Figures 1C,D. The parameter ep was used as an indicator of the
quality of fit, and its averaged value for all animals (n = 40)
studied was 0.0036± 0.0002. A high coefficient of determination
(0.9916 ± 0.0006) and a relatively low standard error of the
estimate (2.11 ± 0.11%) reflected the goodness of fit of the
elastance-resistance model. All these data indicated that the
model-generated parameters Veed and Qmax were acceptable for
the analysis of cardiac pumping mechanics.
Figure 2C demonstrates the end-systolic equilibrium point,
which was determined by drawing a tangential line from Pisomax
to the right corner of the pressure-ejected volume loop (green
curve).
Using the immunohistochemical staining technique, we
demonstrated that the LPS-challenged rats displayed greater
immunoreactivity of RAGE (Figure 3A) and CD68 (Figure 3B)
proteins than did the aged-matched shams. Figure 3 also
shows that MP therapy prevented the LPS-induced increase
in CD68 and RAGE expressions in the rat myocardium. The
immunoreactivities of CD68 and RAGE proteins for each group
were compared with their untreated H&E stains in Figure 3.
Figure 4 shows the effects of MP and LPS on the
expression of myocardial depressants such as peroxynitrite
(A), MDA (B), and HMGB1 (C) in the rats studied. The
SDS-PAGE profiles of the LV HMGB1 protein is shown
in Figure 4D after we performed Western blotting. Cardiac
levels of the aforementioned depressive mediators were higher
in the LPS-treated rats than in the aged-matched shams.
MP therapy prevented the LPS-induced increase in cardiac
HMGB1, peroxynitrite, and MDA levels. Neither HMGB1 nor
peroxynitrite and MDA were attenuated by MP in the Sham
group.
As a mechanical pump, 2 independent features of the left
ventricle can be described using the systolic elastance and
internal resistance. Figure 5 shows the effects of MP and LPS
on the estimated Pisomax (A), Veed (B), Emax (C), and Qmax
(D). LPS challenge reduced Pisomax and significantly increased
Veed, resulting in a marked decrease in Emax. After MP therapy,
the LPS-treated rats significantly reduced Veed and significantly
increased Pisomax and Emax. When normalized for LVW, Emax of
the LPS-MP heart (i.e., Emaxn = Emax/LVW) was still significantly
higher than that of the LPS heart (972.9 ± 75.2 vs. 587.9 ±
33.8mmHg mL−1 g−1, P < 0.001). MP therapy prevented
an LPS-induced increase in Qmax. Neither Emax nor Qmax was
influenced by MP administered to the Sham group.
The association of cardiodynamics and cardiac depressant
substances was shown in Figure 6. At the cardiac tissues, LV
Emax was significantly diminished by the increased peroxynitrite
(r = 0.6276, P < 0.0001 in A) as well as MDA contents
(r = 0.5958, P < 0.0001 in B), respectively. By contrast, as LV
peroxynitrie level was increased by LPS challenge, the rats had an
augmentation in LV Qmax (r = 0.3992, P < 0.05 in C). The LV
Qmax was also in a positive linear relationship with the LV MDA
content (r = 0.3540, P < 0.05 in D).
DISCUSSION
For MP therapy, the range of the applied dosage in rodent is
from 1mg kg−1 to 40mg kg−1 (Ghellioni et al., 2015; Ren et al.,
2015). In 2010, Guess et al. have suggested that short-term, high-
dose glucocorticoid treatment resulted in similar changes in gene
expression and glucocorticoid receptor phosphorylation to that
of long-term, low-dose glucocorticoid treatment (Guess et al.,
2010). Moreover, Annane and Cavaillon (2003) have shown that
a low-dose (but not a high-dose) hydrocortisone can reverse
the systemic inflammatory response, endothelial activation, and
coagulation disorders in subjects secondary to an infection.
At these low doses, prolonged corticosteroid therapy has the
potential to improve rather than to suppress innate immunity
in patients with septic shock (Kaufmann et al., 2008). In the
present study, the low-dose MP therapy protected the LPS-
challenged rats from deterioration in cardiac pumpingmechanics
associated with the reduced cardiac levels of negative inotropic
molecules such as peroxynitrite, MDA, and HMGB1 protein.
Our study results were consistent with the findings of other
studies (Keh et al., 2003; Oppert et al., 2005); prolonged low-dose
corticosteroid treatment attenuates the severity of inflammation
and the intensity and duration of organ system failure.
As mentioned, the ratio of Pisomax to Veed determines the
LV systolic elastance (Emax). In this study, the reduced Emax in
inflammatory heart disease (Figure 5C) was evidenced by the fact
that Pisomax was significant decreased by 14.9% (Figure 5A) and
Veed increased 23.2% (Figure 5B) in rats after LPS challenge. The
diminished cardiac contractility of the inflamed heart indicated
that the myocardium of the LPS-treated rats could not produce
sufficient pressure to support Emax along with the increased Veed.
After MP therapy for 2 weeks, the LPS-associated changes in
both Pisomax and Veed improved the cardiac contractile status,
as shown by a 42.4% increase in Emax. Another feature of
cardiac pumping mechanics that was altered in the LPS-treated
rats was the decreased LV internal resistance, as shown by the
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FIGURE 3 | Effects of LPS and MP on the expression of CD68 (macrophage marker) (A) and RAGE (inflammatory marker) (B) in the myocardium. We
used the immunohistochemical staining technique to probe CD68 (400x) and RAGE (400x) expressions at the cardiac tissues. The sites of antibody staining were
indicated by arrows. LPS, lipopolysaccharide; MP, methylprednisolone; RAGE, receptor for advanced glycation end products.
increase in Qmax (Figure 5D). After MP therapy, a decline in
Qmax indicated that the LV internal resistance of the inflamed
hearts was restored to normal in the LPS-treated rats. In parallel,
the benefits of MP on the LV systolic pumping mechanics
were associated with its ability to reduce the cardiac levels
of peroxynitrite, malondialdehyde, and HMGB1 molecules in
inflammation (Figure 4).
We previously demonstrated that rats challenged with LPS
had concomitant enhancement of advanced glycation end
products (AGEs), RAGE, and iNOS expressions within the vessel
wall (Ko et al., 2013). The interaction of AGEs with its receptor
RAGEmaintained and even amplified inflammatory activities. In
the present study, long-term LPS challenge exerted inflammation
on cardiac tissues, as evidenced by the increased CD68 and
RAGE expressions in the heart (Figure 3). An LPS challenge
also enhanced and prolonged the release of CRP, IL-6, and NO
in the plasma (Table 1). In cardiac tissues, the overproduction
of myocardial peroxynitrite (Figure 4A) in the LPS-treated rats
might be one of the factors responsible for the impaired pumping
mechanics of the inflamed heart. We found that the LV Emax
was significantly inversely associated with the LV peroxynitrite
(Figure 6A), whereas the LVQmax was enhanced by the increased
LV peroxynitrite (Figure 6C). This result was supported by that
of the study by Gao et al. (2003) in which the generation of
myocardial peroxynitrite caused cytokine-induced myocardial
contractile dysfunction. MP therapy for 2 weeks reduced cardiac
peroxynitrite levels in the LPS-treated rats (Figure 4A), restoring
the cardiac contractility (Figure 6A) and LV internal resistance
(Figure 6C) to normal. This MP-induced decline in myocardial
levels of peroxynitrite might partially explain the prevention of
LPS-induced injury in the systolic pumping mechanics of the left
ventricle.
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FIGURE 4 | Effects of LPS and MP on cardiac peroxynitrite (A), MDA (B), and HMGB1 (C) levels. Graph (D) shows the SDS-PAGE profiles of LV HMGB1,
which were electrotransferred onto PVDF membranes by using an anti-HMGB1 antibody. Using β-actin expression as a referred base, the expression of protein was
normalized to calculate the LV HMGB1 content. Cardiac peroxynitrite level was measured using commercially available enzyme-linked immunosorbent assay kits. LV
MDA levels were estimated by TBARS by using a commercial kit. Results are expressed as the mean ± s.e. LPS, lipopolysaccharide; LV, left ventricular; MP,
methylprednisolone; HMGB1, high mobility group box 1; MDA, malondialdehyde (n = 10/group).
LPS stimulation also resulted in concomitant enhancement
of myocardial depressant substances, such as MDA (Figure 4B)
and HMGB1 (Figure 4C), at the cardiac level. MDA is a
highly toxic substance, which is generated by lipid peroxidation
(Slatter et al., 2000). MDA serves as an indirect index of
ROS activity (Gutteridge and Halliwell, 1990) because of its
ability to significantly increase oxidative stress and superoxide
production (Shanmugam et al., 2008). Membrane damage caused
by ROS-induced lipid peroxidation has been considered the
predominant mechanism for cellular membrane dysfunction
and subsequent alteration of cellular functions (Porter et al.,
1995; Dhalla et al., 1996). Thus, the increase in cardiac
MDA levels (Figure 4B) caused by an LPS challenge might
play a negative role in the regulation of cardiac pumping
mechanics. We found that the LV Emax deteriorated with
the increased LV MDA content (Figure 6B). By contrast,
the LV Qmax was augmented by the increased LV MDA
molecule (Figure 6D). This result supports that of the study by
Folden et al. (2003), in which MDA directly induced cardiac
depression because of its ability to enhance oxidative stress
at the ventricular myocyte level. The LPS-induced increase
in myocardial levels of MDA was attenuated by MP therapy
(Figure 4B), and the ability of MP to reduce cardiac MDA
levels might allow the drug to improve the systolic mechanical
behavior of the ventricular pump in the LPS-treated rats
(Figures 6B,D).
Another factor responsible for cardiac contractile dysfunction
associated with endotoxemia is HMGB1 (Hagiwara et al., 2008),
a damage-associated molecular pattern molecule that is actively
secreted by stimulated immune cells and passively released by
nonimmune cells undergoing necrosis (Klune et al., 2008). In the
present study, observed was the association of the myocardial
depressant HMGB1 molecule with the deterioration of cardiac
pumping mechanics regarding Emax and Qmax in rats after an
LPS challenge (Figure 4C). This result was supported by that of
the study by Xu et al. (2010), in which LPS challenge induced
HMGB1 secretion by viable cardiac myocytes, and HMGB1
affected the LPS-induced myocardial contractile dysfunction.
The LPS-induced depression of cardiac pumping mechanics
was prevented by MP therapy, which might be associated with
the attenuation of LPS-induced cardiomyocyte production and
HMGB1 secretion in intact animals.
Although, no mechanisms were provided in this study to
explain how MP reduced those cardiac depressant substances,
Bains and Hall (2012) demonstrated that MP has the potential
to inhibit peroxynitrite and lipid peroxidation-derived MDA
content. The mode of the therapeutic action of glucocorticoids
involves an inhibition of LPS-induced HMGB1 release, which
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FIGURE 5 | Effects of LPS and MP on Pisomax (A), Veed (B), Emax (C), and Qmax (D). The ratio of Pisomax to Veed determines the LV Emax. Results are
expressed as the mean ± s.e. LPS, lipopolysaccharide; LV, left ventricular; MP, methylprednisolone; Pisomax, estimated peak isovolumic pressure; Veed , effective LV
end-diastolic volume; Emax, maximal systolic elastance; Qmax, theoretical maximum flow (n = 10/group).
is mediated by calcium-dependent classical PKC (Oh et al.,
2009). Our study results offer a basic consideration for the
clinical studies exploring the benefits of prolonged low-dose
corticosteroid treatment on cardiac failure in patients with
inflammatory disorder.
Several investigators found that treating rats with MP resulted
in a reduction in BW and an increase in plasma glucose, insulin,
and FFA concentrations (Skjaerbaek et al., 1999; Fang et al.,
2011). Glucose and insulin feedback interactions were extended
to capture the major metabolic effects of FFA in stimulation
of insulin secretion and inhibition of insulin-stimulated glucose
utilization (You et al., 2009). Thus, MP may cause catabolism
to deteriorate insulin action, lowering glucose utilization. As a
result, the body cannot synthesize proteins, ultimately leading
to weight loss. In the present study, we found that there existed
BW loss and higher plasma FFA in both the Sham-MP and LPS-
MP groups. Moreover, no weakness and abnormal death were
observed during the experiment study.
In this study, we provided an approach to consider the clinical
application of an elastance–resistance model in the study of
cardiodynamics. In clinical setting, the indispensable isovolumic
signals obtained by occluding the ascending aorta at the end
of diastole are not permitted in human subjects. This critical
problem could be solved by using a curve-fitting technique to
obtain the isovolumic pressure curve from the instantaneous
pressure of an ejecting contraction (Sunagawa et al., 1980).
With the estimated isovolumic pressure, the elastance–resistance
model showed a satisfactory quality of the model fit when
evaluating the ventricular elastance and resistance. Moreover,
without any perturbation of the loading conditions, the single-
beat estimation technique allowed investigators to compute the
2 aforementioned LV systolic parameters from the pulsatile LV
pressure and ascending aortic flow signals, which were obtained
over a single cardiac cycle.
Certain limitations of this study deserve consideration.
Because both the pulsatile LV pressure and ascending aortic
flow signals cannot be measured in conscious animals, our study
results pertain only to measurements made in the anesthetized
open-chest rat. A fall in blood pressure may occur in this
experimental setting, introducing reflex effects not found in
the close-chest setting (Zuckerman and Yin, 1989). To what
extent the effects of anesthesia and thoracotomy are on pulsatile
cardiac dynamics in the rat remains uncertain. Thus, it should
be emphasized that heart function evaluated under conditions
of anesthesia and open chest is a limitation of this study. This
limitation may also apply to other measurements, such as blood
parameters and histological assessments. Extrapolation of our
observations to intact conscious animals should be done with
caution.
Another disadvantage of this study is that no cardiac
echo examination was performed to compare the functional
phenotype of the heart with the intrinsic activity of the
myocardium obtained by using the elastance-resistance model
analysis. However, in addition to cardiac intrinsic contractility
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FIGURE 6 | Association of cardiodynamic parameters with the cardiac depressant substances. At the cardiac tissues, the LV Emax is inversely related with
either LV peroxynitrite level (A) or LV MDA content (B). By contrast, the LV Qmax increased in response to an increase in LV peroxynitrite level (C) or to the increased
LV MDA content (D). Emax, maximal systolic elastance; Qmax, theoretical maximum flow; MDA, malondialdehyde (n = 10/group).
expressed as Emax, cardiac disease can significantly affect
ventricular resistance in terms of Qmax (Shroff et al., 1983).
Although, there is a practical advantage to perform echography
or telemetry, it is difficult to evaluate ventricular resistance based
on this kind of measurement.
In summary, a concomitant increase in cardiac peroxynitrite,
MDA, and HMGB1 levels was observed in rats with a long-
term LPS challenge. These myocardial depressants might cause
adverse effects on the systolic mechanical behavior of the
ventricular pump regarding Emax and Qmax. After low-dose MP
therapy for 2 weeks, the elevated cardiac levels of peroxynitrite,
malondialdehyde, and HMGB1 molecules were attenuated in
rats with LPS-induced inflammation. In parallel, MP therapy
ameliorated the contractile dysfunction of the left ventricle in
LPS-treated rats, as evidenced by the increase in Emax. Moreover,
administering MP therapy to the LPS-treated animals restored
the reduced LV internal resistance of the inflamed heart to
normal, as shown by the decrease in Qmax. All these findings
suggest that the benefits of low-dose MP on cardiac pumping
mechanics might be associated with its ability to reduce the
aforementioned cardiodepressive molecules in rats with LPS-
induced chronic inflammation.
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